Home
Login
Register
Live
Users
Tag cloud
Published News
Upcoming News
Submit a new story
World Pharma News Home
»
Blogs
»
Scientific Misconduct Blog: ENHANCE trial - CEO saw outcome in piece of toast
->
Get all Published News delivered to your inbox!
(a free service delivered by FeedBurner)
7
Vote
Scientific Misconduct Blog: ENHANCE trial - CEO saw outcome in piece of toast
Posted by
SMB
189 days ago
(
http://scientific-misconduct.blogspot.com
)
View profile
Category
:
Blogs
|
Tags
:
enhance
vytorin
ezetemibe
zetia
toast
The ENHANCE trial (Vytorin) explained. Satire.
Discuss
Add this link to...
Bury
Add to:
|
Bookmarks
Comments
Who Voted
Related Links
Comments
Log in to comment
or register
here
.
Who voted for this story
SMB
worldpharmanews
Jonathon
G00gle
CTim
filipino-news
filipino-ako
Related Links
Drug Injury Watch: Does Debate Over Whether Zetia And Vytorin Are, In Fact, Effective Overshadow The Drug-Safety Aspect?
Pharmalot » From Vytorin To Whytorin? The Enhance Saga
Princess Zetia and the pea
Pharmalot » Has Vytorin Created New FDA Approval Hurdles?
PharmaGossip: Vytorin - PharmaGossip readers have their say
Lawmakers examine Web postings in Vytorin probe
Pharma Chat Board Has Nothing for Congress on Vytorin
Pharmalot » Hassan Comes Clean About Vytorin. Or Did He?
Health Blog: Whither Vytorin? Consider Canada
Pharmalot » What Report? The Vytorin Expert And His Findings
What is World Pharma News?
World Pharma News .net is the first worldwide Web 2.0 pharmaceutical news service developed on the top of the World Pharma News .com Project.
Login
|
Register
Top Today
1
ADAGIO trial results show Azil...
1
Study overturns century-old ru...
Published News
1
Study overturns century-old ru...
1
ADAGIO trial results show Azil...
2
Drug Injury Watch: August 2008...
2
Drug Injury Watch: FDA Warns S...
1
Brings complementary capabilit...
Categories
Blogs
Clinical Trials
Conferences & Events
Corporate
Financial
Product
Publications
Research & Development
Top Tags
bayer
drug-injury
drug-safety
fda
glaxosmithkline
novartis
pfizer
pharma
pharmalot
preemption
read more
Comments